A multi-country, 397-person uncontrolled phase III trial of remdesivir in people with severe COVID-19 (which excluded critically ill people on ventilators but included people receiving supplemental oxygen) compared a 5- vs. 10-day treatment course. Only 44% of the 10-day arm completed treatment, and there was no advantage to lengthening treatment. The authors noted that better outcomes among people who received a 5-day course of remdesivir could be due to their baseline characteristics rather than the effects of the medicine. Viral load test results during and after remdesivir use were not available due to global variation in access. Source
